Blood draw startup Drawbridge Health enters strategic collaboration with wellness business

Thorne Research will get exclusive rights to distribute and commercialize future Drawbridge Health products within the U.S. health and wellness industry and will invest millions in Drawbridge Health.

Drawbridge Health blood draw device

Drawbridge Health, a GE Ventures spinoff that developed a device to draw blood without pain and chemically stabilizes it for transport, has agreed to a strategic collaboration with Thorne Research, a health and wellness business that intends to use Drawbridge Health’s technology to support its personalized wellness programs.

It marks the first partnership since Drawbridge’s launch last month. The company is gearing up for clinical trials with the goal of securing  510(k) clearance from the U.S. Food and Drug Administration for the device.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Drawbridge developed a handheld device that’s applied to the upper arm. Two buttons are pushed, pricking the skin, generating a few drops of blood that flow into the device’s chamber and onto a strip of paper, which acts to stabilize the blood. The paper eliminates the need for refrigeration and extends the sample’s shelf life.

Thorne Research developed blood biomarker tests. It uses the results and analytical software to help develop personalized plans for customers’ diet, exercise and supplements they should take. Its subsidiary WellnessFX developed an app to help consumers schedule blood, genetic and microbiome testing and help them understand the data through phone consultations with health practitioners to examine biomarkers that measure cardiovascular, metabolic, hormonal and nutritional health issues.

As part of the deal, Thorne Research will get exclusive rights to distribute and commercialize future Drawbridge Health products within the U.S. health and wellness industry. In exchange, Thorne Research will invest millions in Drawbridge Health and Thorne Research CEO Paul Jacobson will join the board of directors for Drawbridge, the news release noted.

Wellness is one of the categories Drawbridge Health CEO Lee McCracken identified for his business in an interview last month.

“There’s an interesting subset of the market: specialty diagnostics, companies that are addressing reproductive health, chronic disease management, genetic testing, wellness,” said McCracken. “They’re already running samples, looking for a better experience that’s easier for a patient or consumer of diagnostics.”